Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
In the Biotechnology & Pharmaceuticals technology area, Melior Pharmaceuticals I Inc. currently has 1 pending office action. This filing is being reviewed by 1 distinct examiner within the distinct art unit. This arrangement shows a centralized prosecution effort, with all current office interactions occurring within this specific technical group. This focus may reflect a strategic prioritization of the technology or the current number of active patent applications.
NIEBAUER, RONALD T is the busiest examiner for the company's portfolio. This individual is currently handling the busiest examiner pending office action. Because this action constitutes the entire pending workload, the company's results are dependent on the perspective of this examiner. Practitioners should note that while this allows for consistent arguments, it also focuses prosecution risk on the review of the assigned examiner and art unit. The resolution of this action will define the company's current standing at the patent office.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16737200 | TREATMENT OF TYPE I AND TYPE II DIABETES | NIEBAUER, RONALD T | 70d |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 16737200 | TREATMENT OF TYPE I AND TYPE II DIABETES | NIEBAUER, RONALD T | 1658 | DP | Final Rejection | 70d | Pending | Jan 08, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMelior Pharmaceuticals I Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ronald T Niebauer has the most, with 1 of Melior Pharmaceuticals I Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
